Next Phase Newsletter

A venture capital firm with multiple offices throughout US and outside of US invests in several areas of technology including biotech, medical devices and digital health. The firm participates in venture and growth investments as well as buyouts – allocations can range from $5-200m. The firm is open to global opportunities.  
 
Within the healthcare sector, the firm is highly interested in healthcare IT and also has some interest in medical devices and diagnostics. For devices and diagnostics, the firm has a strong preference for investing in products that have already achieved FDA clearance; only exceptional pre-clearance products will be considered and in those cases, the firm will only look at 510k products that are very close to approval; PMAs will not be considered. The firm is open to all indication areas, and has experience and expertise in diabetes, ENT, metabolic diseases, and the spine; the firm generally does not invest in highly invasive medical devices. The firm may also consider opportunities in laboratory tools and analytical drug discovery tools (but not drug discovery service models). In recent, the firm has expanded their investment areas into biotech and life sciences, and is open to investing across all modalities and indications in both pre-clinical and clinical stage assets. 
 
The firm invests in privately-held companies, and prefers to back experienced management teams with previous entrepreneurial successes. The firm prefers to invest in companies with over $2 million in revenue (over $3 million for healthcare IT companies), and with a customer base that includes large hospital networks or high-profile customers. Defensible IP is also a highly important factor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

An investor group based in the US is an investing ecosystem that includes Accredited Angel Investors, Healthcare Systems, and Corporate Venture Investors.  The firm focuses on healthcare IT, services and digital health from providers to consumers that changes the landscape of healthcare delivery. The firm prides itself in having built an ecosystem of qualified venture investors, corporate leaders and healthcare providers that open doors to strategic expertise and collaboration in the healthcare IT space. As an Angel-stage investor, the firm’s typical investment size can range, and can go from $100,000 to several million dollars. The firm also co-invests, and has made 24 series A/B investments so far, and is expecting 4-5 new investments and 4-5 repeat investments within the next year. The firm is open to companies throughout the USA, and has historically reviewed companies in Canada, though based on experience, prefer those that can manage the logistics of geographical distance. 
 
The firm focuses on healthcare IT, service, and digital health from providers to consumers that have a working prototype with an early pilot traction. The firm seeks products that serve hospitals at all parts of the continuum care spectrum, reaching to chronic care services that are past discharge and into long-term outpatient care. The firm also invests in devices that go to the consumer, as well as software-enabled technologies, such as connection technologies (i.e. Bluetooth, cell phone, etc.). The firm prefers no FDA regulated devices, and looks at pre-revenue technology with a foreseen horizon in terms of potential. The firm is also open to biotools and lab equipment, as they have historically invested in software and service models in the genomics area and technologies that organize clinical trials. 
 
While a management team must be in place, The firm has an experienced team of members with the ability to mentor and fill management teams with expertise. The firm typically takes a board seat after leading an investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm headquartered in Canada likes to be an early-believer and invest in early-stage companies in niche areas that are often overlooked. Interested areas include, but are not limited to, healthcare, food tech, education, clean tech, software and more. The firm only invests in Pre-Seed and Seed stage companies and will typically allocate between $25k-500k USD. The firm has co-led and led rounds, but mainly acts as a co-investor and is open to global companies. 
 
The firm is sector-agnostic and in terms of life science, will invest in devices, health tech, drug discovery, and diagnostics. The firm invests in companies that are pre-phase I and/or in-development. The firm is also indication agnostic. 
 
The firm strongly emphasizes and looks for a dedicated and full-time team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm founded in 2020 and based in the US, is seeking opportunities in the medical devices and digital health sectors of life sciences. The firm is looking to engage in Series A to Series B financing rounds with initial check sizes between 1 – 3 million USD. The firm prefers to lead/co-lead the financing rounds but is open to co-investing. The firm is focused on companies located in North America and Israel. 
 
The firm is interested in early-stage opportunities in medical devices, diagnostics, and digital health sectors but does not invest in therapeutics. The firm is overall opportunistic and will consider various subsectors and indications. For digital health, the firm prefers b-to-b over b-to-c products. The firm will invest in all early-stage companies including pre and post commercial enterprises. 
 
The firm seeks to work with management teams that have prior entrepreneurial experience. The firm prefers to lead financing rounds and will most likely take a board seat when leading. The firm considers themselves an active investor and will work closely with companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

An international family of venture capital funds invests in early-stage, high-growth life science and health technology companies in the US, UK, and Europe. The firm manages both a US and EU based fund. The EU fund primarily provides Series A financing in the range of £2-5M. The EU fund is actively seeking new investment opportunities in the UK and Europe, and the US fund invests in all of US. 
 
The firm is currently seeking to invest in novel early stage biopharma and medical devices opportunities. The firm is opportunistic in terms of subsectors and indications. 
 
The firm requests a board seat in each portfolio company. The firm invests in management teams who are highly driven and tenacious problem solvers.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm with multiple offices in the US partners with and invests in entrepreneurs who are developing breakthrough products leveraging the convergence of biology and/or hardware with advanced computation and AI (referred to as Convergent Tech). The firm employs a multi-stage investment strategy, encompassing both seed and venture investment programs, and assist entrepreneurs with recruiting and customer and supply chain business development. The firm is generally a lead investor, and invests up to $10 million per opportunity; the firm also has an active seed fund that invests smaller amounts at earlier development stages. 
 
The firm is invests in life science start-ups developing advanced materials, process, and device technologies that leverage advanced computational approaches such as deep learning, and unique data generation capabilities. Specific areas of interest include drug discovery platforms, manufacturing platforms, drug delivery platforms, non-invasive diagnostics, and sustainability generally. The firm does not invest in pure-play therapeutic clinical development business models. 
 
The firm favors companies with platform technologies and partnership-based business models. The firm has deep expertise in manufacturing and productization. Additionally, LPs include large pharma and medical device manufacturing companies; the firm helps portfolio companies develop relationships with these strategics. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.